News >

Analysis Explores Continuing Anti-PD-1 Therapy Past Progression in Melanoma

Jason Harris
Published: Friday, Feb 16, 2018

Julia A. Beaver, MD

Julia A. Beaver, MD
Continuing treatment with PD-1 inhibitors after progression is not currently indicated for patients with melanoma, but researchers affiliated with the FDA have suggested there might be value in such a strategy.

Investigators with the FDA’s Center for Drug Evaluation and Research and Oncology Center of Excellence conducted a pooled analysis of all trial reports and data marketing applications for the use of anti–PD-1 antibodies alone or in combination to treat patients with unresectable or metastatic melanoma that allowed for continuation of the antibody beyond RECIST-defined progression in the anti–PD-1 group submitted to the FDA approved before January 1, 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication